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Abstract. Background: Lidocaine and ropivacaine have
been widely used in gastric cancer surgery. In recent years,
lidocaine and ropivacaine have attracted increasing
attention in cancer research, whilst effects of lidocaine and
ropivacaine on gastric cancer cells have not been
investigated before. This study explored the effect of
lidocaine and ropivacaine on AGS and HGC-27 gastric
cancer cells. Materials and Methods: AGS and HGC-27 cells
were incubated with lidocaine or ropivacaine at
concentrations of 10, 100 and 1 mM. At 24, 48 and 72 h
after treatment, proliferation and invasion were evaluated by
crystal violet assay and transwell invasion assay. Electric
cell-substrate impedance sensing was applied to measure the
migration of cancer cells. Phosphorylation status of
extracellular-regulated protein kinases (ERK1/2) was
evaluated by western blot analysis. Results: Lidocaine 
(1 mM) and ropivacaine (1 mM) significantly inhibited the
proliferation of AGS and HG-27 cells, but had no significant
effects on invasion. Lidocaine (1 mM) and ropivacaine 
(1 mM) also inhibited the migration of AGS and HGC-
27cells. After treatment with lidocaine (1 mM) or
ropivacaine (1 mM) for 24 h, the phosphorylation of ERK1/2
in AGS and HGC-27 cells was reduced. Conclusion:
Lidocaine at a clinically relevant concentration (10 μM),
and ropivacaine at 1 mM inhibited the proliferation of
gastric cancer cell lines by down-regulation of p-ERK1/2.
The migration of HGC-27 cells, rather than AGS cells was
more obviously inhibited by lidocaine (1 mM) and
ropivacaine (1 mM). This research is easy to implement, and
lays a foundation for the future research of local anaesthetics
in cancer.
Gastric cancer was the third leading cause of mortality
throughout the world in 2013 (1, 2). Conventional
therapeutic methods for gastric cancer are target-specific
drug treatment (3), surgical excision (4), radiotherapy or
chemotherapy (5). After surgery, the recurrence and
metastasis of gastric cancer are pressing issues, and are
complicated processes involved a series of events (6, 7), such
as tumor heterogeneity, and epigenetic changes (8, 9). It has
been confirmed that circulating tumour cells with the ability
to diffuse and metastasize are a prime prognostic marker for
cancer recurrence (10, 11). Even if patients undergo a
complete resection of their tumour, circulating tumour cells
shed from the tumour into the circulatory or lymphatic
system, enabling the recurrence and metastasis of cancer
(12). Therefore, after surgery cancer patients still need to
take certain anticancer drugs and radiation treatment to
prevent recurrence and metastasis. Anticancer drugs are
usually expensive and have many side-effects (13). There is,
therefore, a pressing need for new economic and highly
effective anticancer drugs.
Local anaesthetics (LAs), which are cheap and affordable,
are widely used peri-operatively to relieve pain by various
modes, such as nerve block, epidural or subarachnoid
injection, local infiltration and intravenous administration. A
study has revealed that LAs have indirect effects on cancer
progression. For example, application of LAs can reduce
opioid consumption or stress response during the perioperative
period (14). In addition, in vitro and in vivo studies showed
that LAs might also have direct effects on certain tumour cells
(e.g. breast, lung, liver and thyroid) (15-18). It has been
reported that lidocaine inhibited the growth of HepG2 cells in
a dose-dependent and time-dependent manner, arrested cells
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in the G0/G1 phase of the cell cycle and induced apoptosis
(19). Lidocaine at 1 mM was also shown to induce cell-cycle
arrest in colon carcinoma cell lines in vitro (20). LAs have
shown cytotoxic effects on neoplastic cells and T-lymphoma
cells in vitro (21). Recent studies have also focused on the
potential effects of LAs on the recurrence and metastasis of
cancer. Growing evidence has shown that LAs can reduce the
recurrence of cancer by indirect ways. For example, LAs have
been shown to cause immunosuppression, stimulate malignant
cells in vitro, induce an inflammatory response, and
neuroendocrine and metabolic stress (22). 
Lidocaine and ropivacaine are both amide-linked LAs
which have been shown to induce apoptosis in human non-
small cell lung cancer; they provoked DNA damage, up-
regulated reactive oxygen species (ROS) production and
activated mitogen-activated protein kinase (MAPK) pathways
(23). Retrospective clinical studies have shown better overall
survival of patients after the application of LAs (22). As
lidocaine and ropivacaine were widely used for anaesthesia
and postoperative analgesia in gastric surgical operations,
herein our study aimed to investigate whether lidocaine and
ropivacaine have effects on gastric cancer cells.
Materials and Methods
Reagents. Commercially available lidocaine (Sigma-Aldrich, Saint
Louis, MO, USA) and ropivacaine hydrochloride (Corden Pharma
S.P.A., Caponago, Italy) were used in this study. Stock solutions of
the agents were prepared by dissolving the drugs in sterile phosphate-
buffered saline (PBS). The final concentration was achieved by
diluting the stock solutions with standard growth medium. 
Cell lines. Human gastric cancer cell lines AGS and HGC-27 were
purchased from the European Collection of Cell Culture (Salisbury,
UK). The cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% foetal calf serum (FCS;
PAA Laboratories Ltd., Somerset, UK), amphotericin B, penicillin
and streptomycin, and incubated at 37˚C in a humidified atmosphere
containing 5% CO2 and 95% humidity.
Cell proliferation assay. Cell cultures cultivated at subconfluence
were washed twice with PBS and detached with 0.05% trypsin-
EDTA. Cells were then re-suspended in culture medium with 10%
foetal bovine serum (FBS), counted, and seeded into 96-well plates
at a density of 3,000 cells/200 μl per well with different
concentrations of lidocaine and ropivacaine, ranging from 0 to 
1 mM. After incubation for 24, 48 and 72 h, the supernatant was
removed and the plates were fixed in 4% formaldehyde (v/v) and
stained with 0.5% (w/v) crystal violet. Subsequently 10% acetic
acid (v/v) was added to the wells to dissolve the formazan crystals
and the plates were incubated on a shaker for 10-15 min. The
absorbance was measured at 540 nm using a Bio-Tek ELx800
multiplate reader (Bio-Tek Instruments Inc., Winnoski, VT, USA)
and expressed as optical density units (OD). 
Invasion assay. Transwell inserts with an 8 μm pore size were coated
with 50 μg Matrigel/100 μl (BD Matrigel™ Basement Membrane
Matrix (Becton, Dickinson and Company, Bedford, OH, USA) and
incubated for 30 min at 37˚C prior to use. The AGS and HGC-27 cells
re-suspended with normal medium including 1% FCS and different
concentrations of lidocaine or ropivacaine (0 μM, 10 μM, 100 μM and
1 mM) were seeded in the upper chambers (1×105 in 200 μl). The
bottom chamber was filled with normal medium (600 μl) enriched
with 10% FBS. After incubation for 24 h, the cells that did not
penetrate the polycarbonate filter membrane were removed with a
clean cotton swab. The cells migrated through the matrix and pores
were fixed with 4% formalin, stained in crystal violet and. The
absorbance was measured at 540 nm using a Bio-Tek ELx800
multiplate reader (Bio-Tek Instruments Inc., Winnoski, VT, USA) and
expressed as optical density units (OD).
Electric cell-substrate impedance sensing (ECIS) analysis of cell
migration. An ECIS 9600 system (Applied Biophysics Inc., Troy, NJ,
USA) was used to detect and track cell adhesion and migration. 96W1E
ECIS arrays were used in the present study. ECIS measures the
interaction between cells and the substrate to which they were attached
via gold-film electrodes placed on the surface of culture dishes. An
identical number of AGS or HGC-27 cells were added into each well,
with different concentrations (0 μM, 10 μM, 100 μM and 1 mM) of
lidocaine or ropivacaine. For the cell migration assay, after 10-h
incubation, confluent cells were wounded. Wounding conditions were
optimised for each cell line (for AGS, 20 s, 3,000 μA, 60,000 Hz; for
HGC-27, 20 s, 1,400 μA, 60,000 Hz). After wounding for up to 4 h,
the migration of the cells was immediately traced again with multiple
frequencies. Cell migration is represented here as resistance variation.
Western blot analysis. The AGS and HGC-27 cells were seeded
into 6-well plates (1×106 cells/well). The protein expression of
phosphorylation status of extracellular-regulated protein kinases
(p-ERK1/2) and β-actin were assessed by western blot, after
incubation with and without 1 mM lidocaine or ropivacaine for 
24 h. The cells were then lysed with lysis buffer and centrifuged
(14,000 × g for 15 min) for the extraction of total protein. The
concentration of total protein was analysed through bicinchoninic
acid assay. Total proteins in each group were separated by 10%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The
proteins were then electrically transferred onto a nitrocellulose
membrane and bound with anti-p-ERK1/2 and β-actin antibodies
(1:2,000; Santa Cruz Biotechnology, Santa Cruz CA, USA)
respectively. The membranes were incubated with secondary anti-
mouse IgG (Sigma-Aldrich). Images of the protein bands were
obtained through a chemiluminescence detection kit (Merck
Millipore, Darmstadt, Germany) and a UvITech imager (UvITech,
Cambridge, UK).
Statistically analysis. IBM SPSS 23 (IBM, Armonk, NY, USA) was
used to identify statistical differences between the test groups
through one-way analysis of variance (ANOVA) tests. All the
experiments in this study were repeated at least three times.
Results
Cell proliferation assay. As shown in Figure 1A and B,
lidocaine suppressed proliferation of AGS and HGC-27 at
concentrations ranging from 10 μM to 1 mM compared with
control. As shown in Figure 1C, ropivacaine at 1 mM
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inhibited the proliferation of AGS cells significantly and the
effects exhibit concentration dependency. For HGC-27 cells
(Figure 1D), ropivacaine at high concentration clearly
inhibited proliferation compared with the control.
Cell migration assay. Compared to the control, 1 mM
lidocaine and 1 mM ropivacaine significantly reduced HGC-
27 cell migration (p=0.024) (Figure 2C and D). No
significant differences were found in those groups using
lower concentrations (p=0.139). Compared with the control
group, 1 mM lidocaine inhibited AGS cell migration
significantly. Ropivacaine had a lesser effect on AGS cell
migration compared with lidocaine and did not lead to
significant differences at any concentration (p=0.718)
(Figure 2A and B).
Cell invasion. Compared to the control group, invasion of
AGS and HGC-27 cells treated with different concentrations
of lidocaine and ropivacaine did differ not significantly
(Figure 3).
Western blot analysis. The quantitative analysis showed that
the phosphorylation of ERK1/2 in AGS and HGC-27 cells
decreased significantly (p=0.001) after treatment with 1 mM
lidocaine and ropivacaine for 24 hours (Figure 4B). 
Discussion
In this study, we found that lidocaine and ropivacaine
inhibited the proliferation of AGS and HGC-27 cells within
72 h, especially lidocaine at doses of 10 μM or above, which
is safe as the blood level for clinical use. 
It has been reported that lidocaine has antiproliferative
effects on human hepatocarcinoma cells, in time-and dose-
dependent manners. (16) Furthermore, a study revealed that
lidocaine suppressed the growth of human hepatocellular
carcinoma in a xenograft model in vivo (17). As lidocaine
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Figure 1. The antiproliferative effects of lidocaine on AGS (A) and HGC-27 (B) cells and of ropivacaine on AGS (C) and HGC-27 (D) cells.
Significantly different at *p<0.05 and **p<0.01 compared with control. The data are means±SD.
can simultaneously inhibit the proliferation of gastric cancer
and liver cancer, whether it has broad-spectrum antitumor
effects still needs further study. It is supposed that by
functional modifications or combination with other drugs,
lidocaine might achieve greater anticancer effects. The
combination of lidocaine with cisplatin has been proposed as
a novel treatment option for hepatocellular carcinoma (19).
In this study, we found that lidocaine significantly inhibited
the proliferation of AGS and HGC-27 cells at an effective
concentration of 10 μM within 72 h with important clinical
significance, whilst ropivacaine had an inhibitory effect on
gastric cells at 1 mM, which is a much higher dose that can
only be achieved by local infiltration clinically. This differs
from the study of Lucchinetti et al. on mesenchymal stem
cells (24), in which the effective concentration was found to
be 100 μM. Our result indicates that lidocaine may be a
better choice than ropivacaine in gastric cancer resection.
In addition, we investigated the effects of lidocaine and
ropivacaine on cell migration. Cell migration is related to
metastasis and recurrence of cancer. Lidocaine at low
concentration exhibited a better effect on cell migration (as
resistance by ECIS) on these two cell lines than ropivacaine,
which indicated that lidocaine may be a good choice to
improve prognosis. 
We also explored the possible mechanism underlying
these effects. Gastric carcinoma cell proliferation is
significantly associated with the activation of the mitogen-
activated protein kinase (MAPK) pathway (25). High
epidermal growth factor receptor (EGFR) levels in gastric
carcinoma are indicated as being associated with disease
prognosis (26). EGFR acts as a cell surface receptor of
extracellular ligands. Activation of EGFR initiates
intracellular signals, including the central RAS/RAF/MAPK
signalling pathway. ERK1/2 was found to be activated in
gastric cancer as the final effectors of MAPK pathway (25).
In this study, we demonstrated that on treatment with 1 mM
lidocaine or ropivacaine, the expression of p-ERK1/2 in
AGS and HGC-27 cells was significantly reduced compared
with the control, suggesting that the antiproliferative effect
of lidocaine and ropivacaine on AGS and HGC-27 cells is
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Figure 2. The effects of lidocaine and ropivacaine on migration, as shown by resistance (Res) using electric cell-substrate impedance sensing, of
AGS (A and B, respectively) and HGC-27 (C and D, respectively) cells. The data are means±SD.
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Figure 3. The effects of lidocaine and ropivacaine on the invasion of HGC cells (A) and AGS cells (B). The data are means±SD.
Figure 4. Western blots (A) and quantitative analysis (B) of phosphorylation of extracellular-regulated protein kinases (p-ERK1/2) in AGS and
HGC-27 cells. **Significantly different at p<0.01 compared with control, after treatment with 1 mM of lidocaine (Lido) and of ropivacaine (Rop)
for 24 h. The data are means±SD.
associated with reduced activation of MAPK pathway by
down-regulating ERK1/2 phosphorylation in vitro.
Compared to other studies, a lower concentration of
lidocaine (10 μM) had an antiproliferative effect on gastric
cancer cells. Wang et al. discovered that lidocaine and
ropivacaine significantly inhibited the migration and invasion
of human non-small cell lung cancer cells (23). In addition,
an in vivo mouse model showed that lidocaine inhibited
distant lung metastasis of murine osteosarcoma cells (27).
However, the concentrations they used were higher than 1
mM. It was reported that lidocaine effectively inhibited the
invasion of human cancer cells (HT1080, HOS, and RPMI-
7951) at 5-20 mM, the concentration of which can only be
achieved by infiltration anaesthesia in surgical operations
(20). A previous study showed that lidocaine and ropivacaine
had no effect on cell viability at concentrations up to 1 mM,
whilst in this study, lidocaine and ropivacaine had
antiproliferative effect on gastric cancer cells (10-1 mM),
especially at 1 mM.
Piegeler et al. reported that lidocaine (10 μM) and
ropivacaine (1 μM) completely blocked the tumor necrosis
factor α-induced increase in invasion of lung adenocarcinoma
cells in vitro (28). We observed that both lidocaine and
ropivacaine at 1 mM and lower concentrations had no effect
on the invasion of gastric cells. The results were similar for
the adhesion and migration of gastric cancer cells with either
lidocaine or ropivacaine at 10 or 100 μM. The inhibitory
effects of LAs on the invasion and migration of cancer cells
may be tissue-specific. 
In conclusion, our study showed that both lidocaine and
ropivacaine can significantly inhibit the proliferation of
gastric cancer cells in vitro. The mechanism was by affecting
the MAPK pathway via reduction of phosphorylation of
EKR1/2. The results implied the additional benefit of the
application of lidocaine and ropivacaine on patients with
gastric cancer during the perioperative period, providing a
reference for future study on gastric cancer surgery.
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